trending Market Intelligence /marketintelligence/en/news-insights/trending/nvkue0d2fidpg0fkdmjp2w2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

CStone Pharmaceuticals completes $260M financing

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


CStone Pharmaceuticals completes $260M financing

China's CStone Pharmaceuticals Co. Ltd. completed a $260 million series B financing.

The funding was led by Singapore sovereign wealth fund GIC Pvt. Ltd. with participation from new investors including Sequoia China, Yunfeng Capital and 6 Dimensions Capital among others.

CStone previously raised $150 million in its series A financing in 2016.

The Chinese biopharmaceutical company plans to use the proceeds to develop its anti-PD-L1 experimental drug, CS1001, and for the expansion of its pipeline.

CS1001 is part of a class of immune system-boosting drugs called checkpoint inhibitors. Inhibitor drugs target immune checkpoints such as PD-L1 and CTLA-4 to prevent cancer cells from downregulating and hiding from the body's immune system.